Business Wire

CA-NEXON-AMERICA

17.3.2021 16:02:05 CET | Business Wire | Press release

Share
Waddle Into War With The New Maestro Class In V4 Global Update

The Maestro, a brilliant tactician wielding both a sword and a pistol, joins Nexon’s MMORPG cross-platform marvel V4 today as its third new class along with new gear and various limited-time reward events, including one special for Amazon Prime members.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005156/en/

A melody crafted through blade and gun, the Maestro is the third class to join V4 since launch. The Maestro uses an enchanted sword and pistol to dole out ranged damage, leading the battle with a variety of brilliant techniques. Equipped with the Rapier main weapon and Magishot sub weapon, he can further shake up combat by switching between Indignant and Composed stances to play the battlefield like a fiddle, letting loose with furious strength or lining up precision attacks against the mightiest foes.

The Maestro Update also introduces two new types of gear, Runes and Crests.

  • Runes are a versatile gear type that improves defense stats by giving between 1 and up to a maximum of 5 traits when enhanced, starting at +6 enhancement. Runes are available from the V4 shop.
  • Crests are supplemental gear that improve a character’s attack through Crit Hit stats. Rare and better crests provide greater strength by also including defense, PVP, and additional Crit DMG stats. Crests can be found in the Arrogant Plains, Despaired Forest, and Land of Evenfall warzones as well as Lunatra battlefields, which require more than 50,000 CP to enter.
  • Both Rune and Crest Enhance Scrolls are required and guarantee up to +2 enhancement, while attempting +3 or higher enhancements may destroy the gear.

To celebrate the arrival of the Maestro, V4 Global players can partake in limited-time reward events including:

  • Costume Giveaway Event: All players who log in after the Maestro update, starting March 17, can redeem a free Rare Costume. The “Valiant King” or “Judgement Queen” costumes will be available on the in-game event page, based on the player’s chosen class.
  • Red Gem Festival Event: The Red Gem Festival will reward players based on the number of Red Gems they have spent since the V4 Global launch, from July 23, 2020 through March 28, 2021. Using the in-game event page, players who have spent more than 300 gems across all characters will receive rewards according to available exchange tables; players who have spent 299 gems or less will also receive a small reward.
  • Amazon Prime Reward Cycles: Starting today, V4 Global players on mobile devices will be able to link their Amazon Prime Account through the in-game menu to receive exclusive rewards once each cycle. Players must link their Amazon Prime accounts during each cycle to receive that cycle’s unique rewards, and the rewards include the Super Starter Pack (containing a 30-day subscription, a Beginner Gear Pack, and a Beginner Accessory Pack) and Rare mounts.

For more information about the all-new V4 Maestro class update, please visit https://www.nexon.com/v4/ or follow @V4Global on Twitter for the latest updates.

Press Assets:

Social: Facebook / Twitter / Instagram / Discord / YouTube

About V4 https://www.nexon.com/v4

Powered by Unreal Engine 4, V4 is a cross-platform free-to-play fantasy MMORPG that gives players the ability to customize their heroes as they defend a breathtaking world from the forces of darkness. With exquisitely detailed battles and offense-focused classes, players can team up with warriors from all over the world on mobile and PC to defeat evil.

About Nexon America Inc. https://www.nexon.com

Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

Social Media:

https://www.facebook.com/V4Global

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye